<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53770">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02070731</url>
  </required_header>
  <id_info>
    <org_study_id>DEFLECT III</org_study_id>
    <nct_id>NCT02070731</nct_id>
  </id_info>
  <brief_title>DEFLECT III: A Prospective, Randomized Evaluation of the TriGuard™ HDH Embolic Deflection Device During TAVI</brief_title>
  <acronym>TAVI</acronym>
  <official_title>A Prospective, Randomized Evaluation of the TriGuard™ HDH Embolic Deflection Device During Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keystone Heart</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keystone Heart</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized evaluation of the TriGuard™ HDH embolic deflection device during transcatheter
      aortic valve implantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TriGuard HDH device is an aortic embolism deflection device intended to reduce the
      amount of embolic material that may enter the carotid, subclavian, and vertebral arteries
      during transcatheter heart valve implantation.

      To assess the safety, efficacy, and performance of the TriGuard HDH embolic deflection
      device in patients undergoing transcatheter aortic valve implantation (TAVI), in comparison
      with patients undergoing unprotected TAVI.

      Subjects with indications for TAVI and who meet study eligibility criteria will be
      randomized 1:1 to one of two treatment arms:

        -  Intervention - TAVI with the TriGuard HDH embolic deflection device

        -  Control - standard unprotected TAVI
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>In hospital procedural safety</measure>
    <time_frame>Up to 7 days during post procedure hospitalization</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>In-hospital procedural safety, defined as the composite of the following Major Adverse Cardiovascular and Cerebrovascular Events (MACCE):
All-cause mortality
All stroke (disabling and non-disabling)
Life threatening (or disabling) bleeding
Acute kidney injury - Stage 2 or 3 (including renal replacement therapy)
Major vascular complications</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>unprotected TAVI</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard unprotected Transcatheter Aortic Valve Implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAVI with the TriGuard HDH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAVI with the TriGuard HDH embolic deflection device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TriGuard HDH</intervention_name>
    <description>TAVI with the TriGuard HDH embolic deflection device</description>
    <arm_group_label>TAVI with the TriGuard HDH</arm_group_label>
    <other_name>TriGuard HDH embolic deflection device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is a male or non-pregnant female ≥18 years of age

          -  Patient meets indications for TAVI

          -  The patient is willing to comply with protocol-specified follow-up evaluations

          -  The patient, or legally authorized representative, has been informed of the nature of
             the study, agrees to its provisions and has provided written informed consent,
             approved by the appropriate Medical Ethics Committee (EC) or Institutional Review
             Board (IRB)

        Exclusion Criteria:

          -  Patients undergoing TAVI via the trans-axillary, trans-subclavian, or trans-aortic
             route

          -  Patients undergoing TAVI via the transapical approach due to friable or mobile
             atherosclerotic plaque in the aortic arch

          -  Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year
             following index procedure. Female subjects of child-bearing potential must have a
             negative pregnancy test done within 7 days prior to index procedure per site standard
             test

          -  Patients with  known diagnosis of acute myocardial infarction (AMI) within 72 hours
             preceding the index procedure (according to definition) or AMI &gt;72 hours preceding
             the index procedure, in whom creatine kinase and creatine kinase-Muscle Brain have
             not returned to within normal limits at the time of procedure.

          -  Patients who are currently experiencing clinical symptoms consistent with new-onset
             AMI, such as nitrate-unresponsive prolonged chest pain

          -  Patients with a history of bleeding diathesis or coagulopathy or patients in whom
             anti-platelet and/or anticoagulant therapy is contraindicated, or who will refuse
             transfusion

          -  Patients with known other mental or physical illness or known history of substance
             abuse that may cause non-compliance with the protocol, confound the data
             interpretation, or is associated with a life expectancy of less than one year

          -  Patients with severe allergy to heparin or known hypersensitivity or contraindication
             to aspirin, heparin/bivalirudin, clopidogrel, nitinol, stainless steel alloy, and/or
             contrast sensitivity that cannot be adequately pre-medicated

          -  Patients with a history of a stroke or transient ischemic attack (TIA) within the
             prior 6 months

          -  Patients with an active peptic ulcer or history of upper gastrointestinal (GI)
             bleeding within the prior 6 months

          -  Patients with renal failure (estimated Glomerular Filtration Rate [estimated
             Glomerular Filtration Rate] &lt;30 mL/min, calculated from serum creatinine by the
             Cockcroft-Gault formula)

          -  Patients with hepatic failure (Child-Pugh class C)

          -  Patients with hypercoagulable states that cannot be corrected by additional
             periprocedural heparin

          -  Patients presenting with cardiogenic shock or severe hypotension (systolic blood
             pressure &lt;90 mm Hg) at the time of the index procedure

          -  Patients with severe peripheral arterial disease that precludes delivery sheath
             vascular access

          -  Patients with a heavily calcified or severely atheromatous aortic arch

          -  Patients with an innominate artery ostium diameter &lt;11 mm

          -  Patients with a transverse aortic diameter &gt;40 mm

          -  Patients with anatomic irregularities of the aortic arch or innominate artery that
             could prevent positioning and stability of the device

          -  Patients with contraindication to cerebral MRI

          -  Patients who have a planned treatment with any other investigational device or
             procedure during the study period

          -  Patients planned to undergo any other cardiac surgical or interventional procedure
             (e.g., concurrent coronary revascularization) during the TAVI procedure or within two
             (2) weeks prior to the TAVI procedure.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Baumbach, Md.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bristol Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Baumbach, Md.</last_name>
    <phone>44 (0) 117 342 6573</phone>
    <email>andreas.baumbach@UHBristol.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital de la Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Gilard, Md.</last_name>
    </contact>
    <investigator>
      <last_name>Martin Gilard, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique chez APHM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Cuisset, Md.</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Cuisset, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxisklinik Herz Und Gefässe</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Spitzer, Md.</last_name>
    </contact>
    <investigator>
      <last_name>Stefan Spitzer, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jochen Reinöhl, Md</last_name>
    </contact>
    <investigator>
      <last_name>Jochen Reinöhl, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical care center</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Schofer, Md.</last_name>
    </contact>
    <investigator>
      <last_name>Joachim Schofer, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Städtische Kliniken Neuss</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Haude, Md.</last_name>
    </contact>
    <investigator>
      <last_name>Michael Haude, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gil Bolotin, Md.</last_name>
    </contact>
    <investigator>
      <last_name>Gil Bolotin, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaarey Tzedek</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giora Weitz, Md.</last_name>
    </contact>
    <investigator>
      <last_name>Giora Weitz, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ferrarotto hospital</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corrado Tamburino, Md.</last_name>
    </contact>
    <investigator>
      <last_name>Corrado Tamburino, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pieter Stella, Md.</last_name>
    </contact>
    <investigator>
      <last_name>Pieter Stella, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Heldick Smith, Md.</last_name>
    </contact>
    <investigator>
      <last_name>David Heldick Smith, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Heart Institute</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Baumbach, Md.</last_name>
    </contact>
    <investigator>
      <last_name>Andreas Baumbach, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Blackman, Md.</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Blackman, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>February 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVR</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
